DSIP

One of the earliest controlled human investigations was published in 1981. Six healthy volunteers participated in a double-blind crossover study and received intravenous DSIP or placebo. Researchers reported increased sleep during an observation period following DSIP administration, along with some changes in subsequent nighttime sleep such as shorter sleep onset and improved sleep efficiency.

This study helped generate significant interest in DSIP. However, only six people participated, which makes it useful as early exploratory research but insufficient to establish a clinical treatment benefit.

DSIP was subsequently investigated in people with chronic insomnia. Some early studies reported improvements in measures such as sleep efficiency, sleep latency, nighttime waking, and daytime alertness. But other controlled studies failed to demonstrate convincing differences from placebo.

One double-blind study involving 16 people with chronic insomnia found some improvement in objective sleep measures, including sleep efficiency and latency. However, the researchers concluded that the effects were weak, several findings could potentially have resulted from changes in the placebo group, and short-term DSIP treatment was unlikely to provide major therapeutic benefit.

A separate double-blind crossover study evaluated DSIP in patients with severe chronic insomnia. Several sleep measures changed during treatment, including total sleep and non-REM sleep. But many differences were not statistically meaningful when properly compared with placebo, and baseline differences complicated interpretation.

The researchers concluded that improvement in sleep under DSIP was of little clinical significance. FDA reached essentially the same overall conclusion when reviewing the available literature in 2026. FDA found that some studies suggested short-term effects on disturbed sleep, while others did not demonstrate meaningful placebo-controlled benefits. The agency characterized the evidence as inconclusive and at best preliminary.

This point is especially important because of the name “Delta Sleep-Inducing Peptide.” The name can make it sound as though DSIP has been proven to reliably produce deep, slow-wave sleep. That has not been established.

For example, a controlled insomnia study found increases primarily in stage 2 sleep, while slow-wave sleep itself was not significantly changed. Later animal research also found that DSIP itself did not consistently increase sleep compared with control treatment, while certain modified DSIP analogs produced stronger slow-wave-sleep effects.

Research over several decades suggests that DSIP may interact with neuroendocrine systems beyond sleep. Older studies and reviews have investigated possible effects involving circadian rhythms, thermoregulation, blood pressure, heart rate, pain thresholds, neurotransmission, stress physiology, and hormonal signaling.

FDA's 2026 pharmacology review concluded that preclinical evidence supports sleep-related biological activity across several species and suggested that some effects may involve opioid-dependent mechanisms and endorphin release, despite DSIP not appearing to directly bind opioid receptors in the conventional sense. These mechanisms remain an area of scientific interest. They are not established clinical benefits.

DSIP was investigated decades ago as a potential treatment for withdrawal from opioids and alcohol. One uncontrolled study reported apparent improvement in withdrawal symptoms following intravenous DSIP administration.

However, FDA's 2026 review identified serious methodological limitations, including small studies, lack of adequate control groups, lack of blinding, different treatment schedules, and subjective outcome measurements. FDA concluded that there is insufficient evidence to determine effectiveness for opioid withdrawal, and no evidence establishing effectiveness through the proposed subcutaneous route. DSIP should therefore not be described as an established opioid-detoxification treatment.

DSIP has also appeared in discussions of narcolepsy. However, FDA found essentially one case report involving a 35-year-old man with narcolepsy. That type of evidence is not sufficient to determine whether DSIP is effective for a chronic neurological disorder. FDA noted that major professional guidelines for narcolepsy do not recommend emideltide/DSIP.